Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Fate Therapeutics, Inc.NASDAQ: FATE
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $31.06M (cash outflow) fell 11.3% year over year, ahead of the -13.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 26.7% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.
Context
- Free cash flow amounted to 1685.8% of revenue in FY2025, up 779.0 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -11.3% holds above the trailing-twelve-month pace of -13.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (112.04M) USD
- Year-over-year change
- +9.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (112.04M) | +9.4% |
| FY2024 | 2024-12-31 | (123.6M) | +10.7% |
| FY2023 | 2023-12-31 | (138.42M) | +51.2% |
| FY2022 | 2022-12-31 | (283.77M) | -32.9% |
| FY2021 | 2021-12-31 | (213.57M) | — |
Free Cash Flow vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.6% is the 6th highest of 10, against a peer median of -8.4%.
- Free cash flow amounts to 1711.4% of revenue for FATE, versus a peer median of 601.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $173.2M USD | -24.7% | +96.0% | 940.4% | |
| LTM Mar 2026 | $150.65M USD | +49.7% | +15.3% | — | |
| LTM Mar 2026 | $108.09M USD | -13.6% | -26.6% | 1711.4% | |
| LTM Mar 2026 | $105.55M USD | +2.9% | +48.5% | — | |
| LTM Mar 2026 | $88.39M USD | -16.3% | -4.8% | — | |
| LTM Mar 2026 | $83.57M USD | -18.6% | -25.7% | — | |
| LTM Mar 2026 | $77.27M USD | -7.3% | +9.1% | — | |
| LTM Mar 2026 | $73.65M USD | +46.6% | +19.8% | — | |
| LTM Mar 2026 | CHF 54.13M CHF | -8.4% | — | — | |
| LTM Mar 2026 | $43.78M USD | -58.6% | -13.4% | 261.8% | |
| Peer median (excluding FATE) | — | -8.4% | +12.2% | 601.1% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 54.36M | 78.73M | 43.46M | 41.5M | 24.92M |
| Change in Working Capital | 2.1M | (34.71M) | 19.18M | (1.96M) | (3.74M) |
| Accounts Receivables | (3.16M) | (29.8M) | 36.65M | (1.11M) | 2.62M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 14.25M | (28.94M) | (1.66M) | (9.03M) |
| Other Working Capital | 5.26M | (19.16M) | 11.47M | 816K | 2.66M |
| Other Non-Cash Items | (13.03M) | (24.27M) | (52.26M) | 4.89M | (247K) |
| Operating Cash Flow | (162.87M) | (248.21M) | (132.26M) | (122.87M) | (106.08M) |
| Capital Expenditures | (50.7M) | (35.57M) | (6.15M) | (730K) | (5.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 362K |
| Purchases of Investments | (968.16M) | (404.8M) | (358.81M) | (317.75M) | (195.14M) |
| Sales of Investments | 694.84M | 607.11M | 477.63M | 330.7M | 311.9M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (324.02M) | 166.75M | 112.67M | 12.22M | 111.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 411.74M | 9.21M | 85K | 94.82M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 41.39M | 0 | 0 | 5.07M | 5.49M |
| Financing Cash Flow | 453.13M | 9.21M | 85K | 99.89M | 5.49M |
| Effect of Forex Changes | 0 | 0 | 50K | 4.95M | 0 |
| Net Change in Cash | (33.76M) | (72.25M) | (19.46M) | (5.81M) | 10.57M |
| Free Cash Flow | (213.57M) | (283.77M) | (138.42M) | (123.6M) | (112.04M) |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.